Reference list

Clinical Studies:

Pulmonary Function

  • Beier, J., K. M. Beeh, S. Pascoe, L. Brookman, G. Peachey, and A. Hmissi. 2009. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm.Pharmacol.Ther. submitted Dec 08.
  • Pascoe, S., K. M. Beeh, L. Brookman, G. Peachey, A. Hmissi, and J. Beier. 2007. Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and IC in patients with COPD. Eur.Respir.J. 30 (Suppl. 51):210s.
  • Beier, J., P. Chanez, J. B. Martinot, A. J. M. Schreurs, R. Tkacova, W. Bao, D. Jack, and M. Higgins. 2007. Safety, tolerability and efficacy of indacaterol, a novel once-daily ß2-agonist, in patients with COPD: a 28-day randomised, placebo-controlled clinical trial. Pulm.Pharmacol.Ther. 20:740-749.
  • Beeh, K. M., J. Beier, R. Buhl, F. Gerken, and N. Metzdorf. 2006. Efficacy of tiotropium (Spiriva®) in patients with COPD switched from previous treatment with short-acting anticholinergics. Proc.Am.Thorac.Soc. 3:A113-Abstract.
  • Beeh, K. M., E. Y. Derom, F. Kanniess, R. Cameron, M. Higgins, and A. van As. 2007. Indacaterol, a novel once-daily ß2-agonist, provides sustained 24-hour bronchodilator efficacy in asthma. Eur.Respir.J. 29:871-878.
  • Beeh, K. M., J. Beier, R. Buhl, P. Stark-Lorenzen, F. Gerken, N. Metzdorf, and ATEM-Studiengruppe. 2006. Wirksamkeit von Tiotropiumbromid (Spiriva®) bei verschiedenen Schweregraden der chronisch-obstruktiven Lungenerkrankung (COPD). Pneumologie 60:341-346.
  • Beeh, K. M., E. Y. Derom, F. Kanniess, R. Cameron, and A. van As. 2005. Indacaterol: the first once-daily beta(2)-agonist with 24-hour bronchodilation. Eur.Respir.J. 26:253s-Abstract.
  • Humbert, M., R. Beasley, J. G. Ayres, R. G. Slavin, J. Hebert, J. Bousquet, K. M. Beeh, S. Ramos, G. W. Canonica, S. Hedgecock, H. Fox, M. Blogg, and K. Surrey. 2005. Efficacy, safety and tolerability of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite GINA 2002 step 4 treatment: INNOVATE. Allergy 60:309-316.
  • Beeh, K. M., J. Beier, R. Buhl, P. Stark-Lorenzen, F. Gerken, and N. Metzdorf. 2004. Efficacy of Tiotropium in patients with mild to moderate COPD. Am.J.Respir.Crit.Care Med. 169:A519-(Abstract).
  • Price, D. B., D. Hernandez, P. Magyar, J. Fiterman, K. M. Beeh, I. G. James, S. Konstantopoulos, R. Rojas, J. A. Van Noord, M. Pons, L. Gilles, and J. A. Leff. 2003. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose budesonide in adult patients with asthma. Thorax 58:211-216.
  • Beier, J., K. M. Beeh, E. W. Schmidt, S. Stenglein, M. Braeutigam, and R. Buhl. 2002. Bodyplethysmographischer Wirkeintritt von Formoterol bei Patienten mit mittel- bis schwergradiger partiell reversibler Atemwegsobstruktion. Pneumologie 56:91-97.
  • Beeh, K. M., J. Beier, O. Kornmann, R. Wiewrodt, and R. Buhl. 2001. Wirksamkeit und Verträglichkeit einer festen Kombination von Salmeterol (50µg) / Fluticason (250µg) in einem einzigen Inhalationssystem (Diskus) bei Patienten mit leicht- bis mittelgradigem Asthma bronchiale. Pneumologie 56:91-97.

 

Exercise Capacity

  • Khindri, S., M. Eeg, A. F. Drollmann, and K. M. Beeh. 2009. The Effect of Indacaterol Maleate on Dynamic Lung Hyperinflation in Patients with COPD. Proc.Am.Thorac.Soc.-(Abstract).

 

Patient-reported Outcomes

  • Beeh, K. M., J. Beier, N. Metzdorf, S. Tonge, and K. Viel. 2006. Diagnose weisende und meist belastende Symptome bei Patienten mit COPD. Pneumologie 60:V282-Abstract.
  • Beeh, K. M., R. Pereno, H. Chen, and P. Jimenez. 2006. Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma. Eur.Respir.J. 28 (Suppl.):440s-Abstract.
  • Chipps, B., R. Buhl, K. M. Beeh, H. Fox, K. Thomas, and C. Reisner. 2006. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr.Med.Res.Op. 22:2201-2208.
  • Beeh, K. M., H. Fox, K. Surrey, and C. Reisner. 2006. Add-on omalizumab significantly improves quality of life in patients with severe persistent allergic (IgE-mediated) asthma: INNOVATE and a pooled analysis. Allergy-(Abstract).
  • Beeh, K. M., H. Fox, P. R. Freeman, S. Hedgecock, and C. Reisner. 2005. Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis. Eur.Respir.J. 26:49s-Abstract.
  • Beeh, K. M., J. Beier, R. Buhl, T. Welte, T. J. Witek, F. Gerken, and N. Metzdorf. 2004. A descriptive analysis of COPD patients in a large cohort in private practices in Germany. Am.J.Respir.Crit.Care Med. 169:A603-(Abstract).

Drug Safety

  • Yang, W. H., J. B. Martinot, P. Pohunek, J. Beier, D. Magula, R. Cameron, R. Owen, and M. Higgins. 2007. Tolerability of indacaterol, a novel once-daily ß2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann.Allergy Asthma Immunol. 99:555-561.
  • Higgins, M., J. Beier, W. H. Yang, A. G. Chuchalin, and R. Owen. 2008. Cardiac Safety of Indacaterol, a Novel Once-Daily Bronchodilator. Proc.Am.Thorac.Soc.-Abstract.
  • Meyer, M., K. M. Beeh, J. Beier, D. Beyer, E. Aydt, R. Zahlten, B. Jilma, and G. Wolff. 2007. Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males. Br.J.Clin.Pharmacol. 63:451-458.
  • Beier, J., D. Jack, W. Bao, and M. Higgins. 2005. Safety of multiple-dose QAB149, a novel 24-hour ß2 agonist, in patients with moderate to severe COPD. Eur.Respir.J. 26:295s-Abstract.

 

Study Design issues and Review Articles

  • Beeh, K. M., B. Hederer, T. Glaab, A. Mueller, M. P. Rutten-van Molken, S. Kesten, and C. Vogelmeier. 2009. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int.J.COPD 4:119-124.
  • Beeh, K. M. and J. Beier. 2009. Indacaterol: a new once-daily long-acting beta2 adrenoceptor agonist. Core Evidence in press.
  • Beeh, K. M. and T. Glaab. 2008. Is there a role for antiinflammatory treatment in COPD ? J.COPD submitted.
  • Beeh, K. M., J. Beier, A. Esperester, and L. D. Paul. 2008. Antiinflammatory properties of ambroxol. Eur.J.Med.Res. 13:557-562.
  • Beeh, K. M. and J. Beier. 2007. Praktische Aspekte der anti-IgE Behandlung: Patientenauswahl und Therapie-Monitoring. Allergologie 30:334-337.
  • Beeh, K. M. 2007. Which patients should be treated with anti-IgE ? Eur.Respir.Rev. 16:85-87.
  • Beeh, K. M. and P. Kardos. 2004. Omalizumab - der Spezial-Agent im therapeutischen Arsenal. MedReview 5:20-21.
  • Beeh, K. M. 2004. Wirksamkeit von Tiotropium (Spiriva) bei COPD. MedReview 5:17-21.
  • Beeh, K. M. and R. Buhl. 2001. Asthma pathogenesis - implications for novel therapies. Med.Klin. 96:15-25.

 

Antiinflammatory Treatment and Challenge Models

  • Groenke, L., K. M. Beeh, R. Cameron, O. Kornmann, J. Beier, M. Shaw, O. Holz, R. Buhl, H. Magnussen, and R. A. Joerres. 2008. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm.Pharmacol.Ther. 21:409-417.
  • Pascoe, S., F. Kanniess, J. Bonner, P. Lloyd, P. Lowe, J. Beier, and R. Woessner. 2006. A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma. Eur.Respir.J.-Abstract.
  • Kanniess, F., J. Beier, K. M. Beeh, K. Hertzberg, I. Delin, M. Kumlin, R. Koenen, D. Bredenboeker, S. E. Dahlen, and H. Magnussen. 2006. Effects of roflumilast on exhaled NO, airway hyperresponsiveness, and inflammatory markers in patients with asthma. Eur.Respir.J. 28 (Suppl.):670s-Abstract.
  • Beeh, K. M., J. Beier, M. Meyer, R. Buhl, R. Zahlten, and G. Wolff. 2006. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: A randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm.Pharmacol.Ther. 19:233-241.
  • Beeh, K. M. and J. Beier. 2006. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma ? Clin.Exp.Allergy 36:142-157.
  • Beier, J. and K. M. Beeh. 2005. Perspektiven der antiinflammatorischen Pharmakotherapie der COPD: Neutrophile im Fokus. Pneumologie 59:770-782.
  • Kanniess, F., J. Beier, S. Janicki, K. Richter, K. M. Beeh, R. Buhl, and H. Magnussen. 2004. Effect of two single doses of the oral beta-1 integrin antagonist SB683698 vs inhaled Fluticasone Propionate on allergen-induced bronchoconstriction in mild asthma. Am.J.Respir.Crit.Care Med. 169:A323.
  • Kanniess, F., J. Beier, J. Kleine-Tebbe, and H. Magnussen. 2004. Effect of inhaled EPI-12323 on allergen response in allergic asthmatics. Am.J.Respir.Crit.Care Med. 169:A322.

 

Inflammometrics and basic Methodology Research

  • Beeh, K. M., C. Heilmann, E. Schlehuber, and J. Beier. 2006. Repeatability study comparing plethysmographic and spirometric lung function parameters in COPD patients, asthmatics, and healthy subjects. Eur.Respir.J. 28 (Suppl.):221s-Abstract.
  • Korn, S., J. Beier, C. Heilmann, O. Kornmann, R. Buhl, and K. M. Beeh. 2005. Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions. Respir.Med. 99:1595-1599.
  • Pohl, D., J. Beier, R. Buhl, and K. M. Beeh. 2005. Effect of histamine and adenosine 5'-monophosphate provocation on sputum neutrophils and related mediators in atopic patients. Ann.Allergy Asthma Immunol. 95:197-203.
  • Beier, J., Beeh, K. M., and Buhl, R. 2004. Sputum levels of reduced glutathione increase 24 hours after allergen challenge in isolated early, but not dual asthmatic responders. Am. J. Respir. Crit. Care Med. 169: A568 (Abstract)
  • Beier, J., K. M. Beeh, O. Kornmann, and R. Buhl. 2004. Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. J.Lab.Clin.Med. 144:38-44.
  • Beeh, K. M., O. Kornmann, R. Buhl, S. V. Culpitt, M. A. Giembycz, and P. J. Barnes. 2003. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 123:1240-1247.
  • Beeh, K. M., J. Beier, N. Koppenhoefer, and R. Buhl. 2004. Increased glutathione disulfide and nitrosothiols in COPD sputum supernatant. Chest 126:1116-1122.
  • Beier, J., K. M. Beeh, D. Semmler, N. Beike, and R. Buhl. 2004. Increased concentrations of glutathione in induced sputum in patients with mild or moderate allergic asthma. Ann.Allergy Asthma Immunol. 92:459-463.
  • Beier, J. 2003. Methodical and clinical aspects of the determination of glutathione in induced sputum in bronchopulmonary disease. Pneumologie 57:101-103.
  • Beier, J., K. M. Beeh, O. Kornmann, and R. Buhl. 2003. Sputum induction leads to a decrease of exhaled nitric oxide unrelated to airflow. Eur.Respir.J. 22:354-357.
  • Beier, J., K. M. Beeh, D. Semmler, and R. Buhl. 2004. Sputum levels of reduced glutathione increase 24 hours after allergen challenge in isolated early, but not dual asthmatic responders. Int.Arch.Allergy Immunol. 135:30-35.
  • Beier, J., K. M. Beeh, O. Kornmann, E. Morankic, N. Ritter, and R. Buhl. 2003. Dissimilarity between seasonal changes in airway responsiveness to adenosine-5'-monophosphate and methacholine in patients with grass pollen allergic rhinitis: relation to induced sputum inflammatory markers. Int.Arch.Allergy Immunol. 132:76-81.
  • Beier, J., D. Semmler, K. M. Beeh, O. Kornmann, and R. Buhl. 2003. Repeatability of pulmonary function kinetics during allergen-induced early and late phase asthmatic reactions. Am.J.Respir.Crit.Care Med. 167:A140-(Abstract).
  • Beeh, K. M., J. Beier, O. Kornmann, C. Meier, T. Taeumer, and R. Buhl. 2003. A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic patients with seasonal allergic rhinitis: correlation with plasma IL-5. Clin.Exp.Allergy 33:475-482.
  • Beier, J., K. M. Beeh, O. Kornmann, and R. Buhl. 2003.Sputum induction leads to a decrease of exhaled nitric oxide unrelated to airflow. Eur.Respir.J. 22:354-3 
DE  EN